Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Y. H. Andrew Wu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5122812455. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 10

  1. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. First author DOI 10.1038/s41416-025-03294-w↗
  2. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  3. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… First author DOI 10.1038/s41416-025-03025-1↗
  4. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  5. Feasibility of laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) as a standard treatment for distal resectable pancreatic cancer. Co-author DOI 10.1007/s00423-023-02942-0↗
  6. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  7. Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005395↗
  8. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Co-author DOI 10.1002/jhbp.1049↗
  9. Author response to: Comment on: Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Data… First author DOI 10.1093/bjs/znac340↗
  10. Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology. Co-author DOI 10.21037/jgo-21-119↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Atsushi Oba · 6 shared papers, 2021–2023 · strength 0.95
  2. Marco Del Chiaro · 4 shared papers, 2021–2023 · strength 0.62
  3. Richard David Schulick · 4 shared papers, 2021–2023 · strength 0.62
  4. Yosuke Inoue · 4 shared papers, 2022–2023 · strength 0.58
  5. Yu Takahashi · 3 shared papers, 2022–2023 · strength 0.42
  6. Yoshihiro Ono · 2 shared papers, 2023 · strength 0.34
  7. Takashi Sasaki · 2 shared papers, 2023 · strength 0.29
  8. Naoki Sasahira · 2 shared papers, 2023 · strength 0.29
  9. Sohei Satoi · 2 shared papers, 2022–2023 · strength 0.24
  10. Thilo Hackert · 2 shared papers, 2022–2023 · strength 0.24
  11. Yuichi Nagakawa · 2 shared papers, 2022–2023 · strength 0.24
  12. Christopher L. Wolfgang · 2 shared papers, 2022–2023 · strength 0.24
  13. Marc G. Besselink · 2 shared papers, 2022–2023 · strength 0.24
  14. Shoki Sato · 1 shared paper, 2023 · strength 0.18
  15. Hiromichi Ito · 1 shared paper, 2023 · strength 0.18
  16. Tomotaka Kato · 1 shared paper, 2023 · strength 0.18
  17. Yu Takahashi · 1 shared paper, 2023 · strength 0.16
  18. Masato Ozaka · 1 shared paper, 2023 · strength 0.16
  19. Kojiro Omiya · 1 shared paper, 2023 · strength 0.16
  20. Hiromichi Ito · 1 shared paper, 2023 · strength 0.16
  21. Akio Saiura · 1 shared paper, 2023 · strength 0.16
  22. Ronggui Lin · 1 shared paper, 2021 · strength 0.15
  23. Shuichi Watanabe · 1 shared paper, 2021 · strength 0.15
  24. Toshitaka Sugawara · 1 shared paper, 2023 · strength 0.13
  25. Yoo‐Seok Yoon · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.